119 related articles for article (PubMed ID: 25217986)
21. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.
Bettinger D; Gkika E; Schultheiss M; Glaser N; Lange S; Maruschke L; Buettner N; Kirste S; Nestle U; Grosu AL; Thimme R; Brunner TB
BMC Cancer; 2018 Aug; 18(1):807. PubMed ID: 30092781
[TBL] [Abstract][Full Text] [Related]
22. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
[TBL] [Abstract][Full Text] [Related]
23. Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study.
Jiang N; Zhang Z; Yin X; Qiu H; Yan W; Hao Y; Yang W; Li H; Xu A; Mu K
Radiol Med; 2024 Apr; 129(4):631-642. PubMed ID: 38355907
[TBL] [Abstract][Full Text] [Related]
24. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Zheng Y; Xiang Y; Shi H; Lin Z; Cheng S; Zhu J
J Hepatocell Carcinoma; 2024; 11():1079-1093. PubMed ID: 38882440
[TBL] [Abstract][Full Text] [Related]
25. Prognostic benefit of preoperative transarterial chemoembolization in upfront resectable large hepatocellular carcinoma: a multicentric propensity score based analysis of European high-volume centers.
Giannone F; Felli E; Cipriani F; Branciforte B; Rhaiem R; Al Taweel B; Brustia R; Salame E; Panaro F; Sommacale D; Piardi T; Torzilli G; Aldrighetti L; Schuster C; Pessaux P
HPB (Oxford); 2024 Jun; 26(6):840-850. PubMed ID: 38553263
[TBL] [Abstract][Full Text] [Related]
26. Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.
Pinato DJ; D'Alessio A; Fulgenzi CAM; Schlaak AE; Celsa C; Killmer S; Blanco JM; Ward C; Stikas CV; Openshaw MR; Acuti N; Nteliopoulos G; Balcells C; Keun HC; Goldin RD; Ross PJ; Cortellini A; Thomas R; Young AM; Danckert N; Tait P; Marchesi JR; Bengsch B; Sharma R
Clin Cancer Res; 2024 Jun; 30(11):2433-2443. PubMed ID: 38578610
[TBL] [Abstract][Full Text] [Related]
27. Transarterial Chemoembolization Plus Tyrosinkinase Inhibitors and PD-1 Inhibitors for Spontaneously Ruptured Hepatocellular Carcinoma.
Ji J; Zhou C; Yan LL; Ma Y; Xu C; Wang FA; Zhou WZ; Lv PH
Cardiovasc Intervent Radiol; 2024 Mar; 47(3):299-309. PubMed ID: 38291158
[TBL] [Abstract][Full Text] [Related]
28. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis.
Li Z; Li Q; Wang X; Chen W; Jin X; Liu X; Ye F; Dai Z; Zheng X; Li P; Sun C; Liu X; Zhang Q; Luo H; Liu R
Cancer Med; 2021 Dec; 10(23):8432-8450. PubMed ID: 34655179
[TBL] [Abstract][Full Text] [Related]
29. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Gao B; Yang F; Zheng D; Hu S; Liu J; Liu H; Liu Y; Liu L; Wang R; Zhao Y; Cui C; Fang C; Yang J; Su S; Han Y; Yang X; Li B
J Hepatocell Carcinoma; 2023; 10():2265-2276. PubMed ID: 38107541
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma in Children and Adolescents: Clinical Characteristics and Treatment.
Wang J; Mao Y; Liu Y; Chen Z; Chen M; Lao X; Li S
J Gastrointest Surg; 2017 Jul; 21(7):1128-1135. PubMed ID: 28397025
[TBL] [Abstract][Full Text] [Related]
31. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
[TBL] [Abstract][Full Text] [Related]
32. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
Zhang L; Sun T; Sun B; Zhang K; Zheng Y; Li N; Chen L; Zheng C; Liang B; Shi H
BMC Cancer; 2024 Feb; 24(1):223. PubMed ID: 38365678
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Body Radiation Therapy With or Without Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone in Early-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Dumago MP; Agas RAF; Jainar CJE; Yap ET; Co LBA; Ortin TTS
J Gastrointest Cancer; 2023 Dec; 54(4):1058-1070. PubMed ID: 37306936
[TBL] [Abstract][Full Text] [Related]
34. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G; Li W; Zang M; Li R; Li Q; Hu X; Zhang Q; Huang W; Ruan J; Pang H; Chen J
Discov Oncol; 2024 Mar; 15(1):68. PubMed ID: 38460053
[TBL] [Abstract][Full Text] [Related]
35. Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period.
Su K; Wang F; Li X; Chi H; Zhang J; He K; Wang Z; Wen L; Song Y; Chen J; Wu Z; Jiang Y; Li H; Gu T; Wang C; Li Y; Liu M; Guo Q; Xu K; Guo L; Han Y
Front Immunol; 2023; 14():1265959. PubMed ID: 37818373
[TBL] [Abstract][Full Text] [Related]
36. [Clinical features and prognostic analysis of transarterial chemoembolization combined with targeted immunotherapy in the treatment of patients with hepatitis B virus-related intermediate-and advanced-stage hepatocellular carcinoma with secondary cholestasis].
Wang NN; Shen JM; Li HL; Wang X; Yang GD; Pan XC; Li J
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1149-1155. PubMed ID: 38238947
[No Abstract] [Full Text] [Related]
37. Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching.
Shimose S; Iwamoto H; Niizeki T; Tanaka M; Shirono T; Moriyama E; Noda Y; Nakano M; Suga H; Kuromatsu R; Torimura T; Koga H; Kawaguchi T
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762018
[TBL] [Abstract][Full Text] [Related]
38. Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma.
Liu W; Xie Z; Shen K; Jiang L; Liu C; Ge Y; Yu J; Jia W; Ma J; Chen H
Med Oncol; 2023 Jul; 40(9):251. PubMed ID: 37498394
[TBL] [Abstract][Full Text] [Related]
39. Letter to the editor regarding "Comparing long-term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial chemoembolization: A propensity score matched study".
Xie Y; Wang J; Zou Y
Eur J Radiol; 2024 Jan; 170():111211. PubMed ID: 37992610
[No Abstract] [Full Text] [Related]
40. Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.
Long T; Yang Z; Zeng H; Wu W; Hu Z; Yang Z; Hu D; Zhou Z; Chen M; Zhang Y
J Hepatocell Carcinoma; 2023; 10():1849-1859. PubMed ID: 37881221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
